Hong Kong's PAG Acquires $540m Majority Stake In Hisun's Biosimilars Arm
Asia-focused PE firm PAG has purchased a majority stake in Hisun BioRay, the biotech division of Chinese state-owned generic company Zhejiang Hisun Pharmaceutical, for $540m, boosting its presence in a nascent, fast-growing segment of the country’s drug industry.
You may also be interested in...
During Q3, biopharma company fundraising reached $13.3bn, mostly from follow-on public offerings, which again made up the most of those dollars. Despite numerous deals valued at $100m+, M&A activity was the lowest of the year. Many of the biggest partnership deals were centered around the inflammation/immune area.
Biocon has joined the march of Indian firms into China, tying up with Chinese firm CMS to sell three generic formulations in the world’s second-largest drug market.
The Asia Pacific region presents large potential opportunities for the development of biosimilar versions of big-selling original biologics as these come out of protection in the major markets. However the regulatory, reimbursement and commercial situation varies greatly country-by-country, presenting a complex mix of factors affecting the overall market outlook for these up and coming biosimilar products.